137 related articles for article (PubMed ID: 1643820)
21. Efficacy and tolerance of oral ofloxacin in treating various infections.
Giamarellou H; Tsagarakis J
Drugs; 1987; 34 Suppl 1():119-23. PubMed ID: 3481312
[TBL] [Abstract][Full Text] [Related]
22. Intravenous ofloxacin in severe infections.
Graninger W; Presterl E; Walzl B; Lackner R; Haslinger B; Hackl W
J Antimicrob Chemother; 1990 Nov; 26 Suppl D():123-35. PubMed ID: 2286587
[TBL] [Abstract][Full Text] [Related]
23. A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial.
Arcieri G; Griffith E; Gruenwaldt G; Heyd A; O'Brien B; Screen P; Becker N; August R
J Clin Pharmacol; 1988 Feb; 28(2):179-89. PubMed ID: 3360968
[TBL] [Abstract][Full Text] [Related]
24. Ciprofloxacin: an update on clinical experience.
Arcieri G; Griffith E; Gruenwaldt G; Heyd A; O'Brien B; Becker N; August R
Am J Med; 1987 Apr; 82(4A):381-6. PubMed ID: 3555063
[TBL] [Abstract][Full Text] [Related]
25. Clinical experience with ofloxacin (DL-8280) in the therapy of various infections.
Cristiano P; Iovene MR; Morelli G; Mandia L; Paradisi F; Altucci P
J Chemother; 1989 Apr; 1(2):107-9. PubMed ID: 2732779
[TBL] [Abstract][Full Text] [Related]
26. Oral ofloxacin: a critical review of the new drug application.
Sanders WE
Clin Infect Dis; 1992 Feb; 14(2):539-54. PubMed ID: 1554843
[TBL] [Abstract][Full Text] [Related]
27. Intravenous followed by oral ofloxacin in the treatment of community acquired lower respiratory tract infections in adults requiring hospitalisation.
Liam CK; Aziah AM; Lim KH; Wong CM
Med J Malaysia; 2000 Sep; 55(3):304-7. PubMed ID: 11200708
[TBL] [Abstract][Full Text] [Related]
28. [Bone infections: treatment by ofloxacin. Apropos of 10 cases].
Bernard E; Etesse H; Garraffo R; Giaume F; Dellamonica P
Pathol Biol (Paris); 1987 May; 35(5):644-7. PubMed ID: 3302877
[TBL] [Abstract][Full Text] [Related]
29. Ceftazidime in the therapy of serious Gram-negative bacillary infections.
Pottage JC; Karakusis PH; Fliegelman RM; Levin S; Trenholme GM
J Antimicrob Chemother; 1983 Jul; 12 Suppl A():223-8. PubMed ID: 6352623
[TBL] [Abstract][Full Text] [Related]
30. [Fluoroquinolones--a new and important group of antimicrobial agents].
Sander J
Tidsskr Nor Laegeforen; 1992 Jan; 112(3):346-9. PubMed ID: 1553674
[TBL] [Abstract][Full Text] [Related]
31. Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients.
Winston DJ; Ho WG; Bruckner DA; Gale RP; Champlin RE
Am J Med; 1990 Jan; 88(1):36-42. PubMed ID: 2153006
[TBL] [Abstract][Full Text] [Related]
32. Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria.
Preheim LC; Cuevas TA; Roccaforte JS; Mellencamp MA; Bittner MJ
Am J Med; 1987 Apr; 82(4A):295-300. PubMed ID: 3555051
[TBL] [Abstract][Full Text] [Related]
33. Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group.
Mattina R; Cocuzza CE; Cesana M
Infection; 1993; 21(2):106-11. PubMed ID: 8387963
[TBL] [Abstract][Full Text] [Related]
34. A prospective study of ofloxacin in acute exacerbations of chronic respiratory disease associated with Pseudomonas aeruginosa.
Meek JC; Maesen FP; Davies BI
J Antimicrob Chemother; 1989 Sep; 24(3):447-53. PubMed ID: 2808196
[TBL] [Abstract][Full Text] [Related]
35. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
Martin SJ; Jung R; Garvin CG
Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
[TBL] [Abstract][Full Text] [Related]
36. Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria.
Eron LJ; Harvey L; Hixon DL; Poretz DM
Antimicrob Agents Chemother; 1985 Aug; 28(2):308-10. PubMed ID: 2939795
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of intravenous ofloxacin: a French multicentre trial in 185 patients.
Mouton Y; Leroy O; Beuscart C; Sivery B; Senneville E; Chidiac C; Beaucaire G; Vincent du Laurier M
J Antimicrob Chemother; 1990 Nov; 26 Suppl D():115-21. PubMed ID: 2286586
[TBL] [Abstract][Full Text] [Related]
38. Clinical safety and efficacy of ofloxacin.
Marone P; Concia E; Grossi P; Malfitano A; Perversi L
Chemioterapia; 1988 Oct; 7(5):320-2. PubMed ID: 3224401
[TBL] [Abstract][Full Text] [Related]
39. Ofloxacin use in a geriatric population.
Nicolle LE; Degelau J; Alessi P; Cullison J; Meyers B
Chemotherapy; 1991; 37 Suppl 1():49-54. PubMed ID: 2049965
[TBL] [Abstract][Full Text] [Related]
40. Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections.
Sanders WE
Rev Infect Dis; 1988; 10(3):528-43. PubMed ID: 3293158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
